Dishman Carbogen Amcis DCAL
CDMO for high-potency APIs and late-stage/commercial molecules via Swiss subsidiary Carbogen Amcis
Mapped in 1 theme: Pharmaceuticals.
Where Dishman Carbogen Amcis sits in the supply chain
Dishman Carbogen Amcis appears in 1 supply-chain layer in one theme, Pharmaceuticals.
Pharmaceuticals › CDMO & contract research
Direct supplierOther companies in this layer
Revenue and profit
| ₹ Cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 2,616 | 2,712 | 2,932 |
| Net profit | −153 | 3 | 97 |
Latest-year revenue ₹2,932 Cr (FY26, company-wide). Wider screens show FY22 onwards.
Strengths
- Swiss/European CDMO footprint valued by Western customers seeking non-China supply
Risks
- Weak profitability (very low ROE) and impairments
- High-cost European operations
Common questions
What does Dishman Carbogen Amcis do?
CDMO for high-potency APIs and late-stage/commercial molecules via Swiss subsidiary Carbogen Amcis.
Where does Dishman Carbogen Amcis sit in the supply chain?
Dishman Carbogen Amcis (NSE: DCAL) is mapped in 1 supply-chain layer: CDMO & contract research (Pharmaceuticals).
Who are Dishman Carbogen Amcis' peers?
In the CDMO & contract research layer of Pharmaceuticals: Divi's Laboratories, Syngene International, Sai Life Sciences, Anthem Biosciences, Cohance Lifesciences, Piramal Pharma and 4 more.
What is Dishman Carbogen Amcis' market cap and valuation?
As of 30 Oct 2026: market cap ₹2,279 Cr, P/E 126.0x, ROCE 3.1%, ROE 1.6%, dividend yield 0%.